Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Liver Diseases

  Free Subscription

Articles published in Gut

Retrieve available abstracts of 252 articles:
HTML format

Single Articles

    July 2021
  1. SHENG J, Zhang J, Wang L, Tano V, et al
    Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny.
    Gut. 2021 Jul 12. pii: gutjnl-2021-324339. doi: 10.1136/gutjnl-2021-324339.
    PubMed     Abstract available

    June 2021
  2. PARK H, Yoon EL, Cho S, Jun DW, et al
    Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.
    Gut. 2021 Jun 14. pii: gutjnl-2021-325102. doi: 10.1136/gutjnl-2021-325102.

  3. CHEUNG CCL, Goh D, Lim X, Tien TZ, et al
    Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19.
    Gut. 2021 Jun 2. pii: gutjnl-2021-324280. doi: 10.1136/gutjnl-2021-324280.

    May 2021
  4. SUN J, Wu G, Pastor F, Rahman N, et al
    RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.
    Gut. 2021 May 21. pii: gutjnl-2020-323126. doi: 10.1136/gutjnl-2020-323126.
    PubMed     Abstract available

    April 2021
  5. YADAV DK, Singh A, Zhang Q, Bai X, et al
    Involvement of liver in COVID-19: systematic review and meta-analysis.
    Gut. 2021;70:807-809.

    March 2021
  6. JACKSON K, Davidson R, Aujayeb A
    Hepatic hydrothorax in the management of cirrhosis.
    Gut. 2021 Mar 31. pii: gutjnl-2021-324698. doi: 10.1136/gutjnl-2021-324698.

  7. HERNAEZ R, Thimme R
    End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma.
    Gut. 2021 Mar 30. pii: gutjnl-2021-324288. doi: 10.1136/gutjnl-2021-324288.

  8. SAPENA V, Enea M, Torres F, Celsa C, et al
    Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
    Gut. 2021 Mar 19. pii: gutjnl-2020-323663. doi: 10.1136/gutjnl-2020-323663.
    PubMed     Abstract available

  9. ZHAN K, Liao S, Li J, Bai Y, et al
    Risk factors in patients with COVID-19 developing severe liver injury during hospitalisation.
    Gut. 2021;70:628-629.

  10. KIM DH, Hong SB, Choi SH, Kim SY, et al
    Surveillance failure in ultrasound for hepatocellular carcinoma: a systematic review and meta-analysis.
    Gut. 2021 Mar 1. pii: gutjnl-2020-323615. doi: 10.1136/gutjnl-2020-323615.

    February 2021
  11. FROMME M, Schneider CV, Pereira V, Hamesch K, et al
    Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency.
    Gut. 2021 Feb 25. pii: gutjnl-2020-323729. doi: 10.1136/gutjnl-2020-323729.
    PubMed     Abstract available

  12. PENEAU C, Imbeaud S, La Bella T, Hirsch TZ, et al
    Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma.
    Gut. 2021 Feb 9. pii: gutjnl-2020-323153. doi: 10.1136/gutjnl-2020-323153.
    PubMed     Abstract available

    January 2021
  13. YASKOLKA MEIR A, Rinott E, Tsaban G, Zelicha H, et al
    Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial.
    Gut. 2021 Jan 18. pii: gutjnl-2020-323106. doi: 10.1136/gutjnl-2020-323106.
    PubMed     Abstract available

  14. AOKI S, Inoue K, Klein S, Halvorsen S, et al
    Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
    Gut. 2021 Jan 11. pii: gutjnl-2020-322493. doi: 10.1136/gutjnl-2020-322493.
    PubMed     Abstract available

  15. BELLINGHAUSEN C, Pletz MW, Rupp J, Witzenrath M, et al
    Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia.
    Gut. 2021;70:221-222.

  16. PETROFF D, Batz O, Jedrysiak K, Kramer J, et al
    Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples.
    Gut. 2021;70:219-221.

    December 2020
  17. SVICHER V, Salpini R, Piermatteo L, Carioti L, et al
    Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B.
    Gut. 2020 Dec 21. pii: gutjnl-2020-323300. doi: 10.1136/gutjnl-2020-323300.
    PubMed     Abstract available

  18. SONG S, Shi Y, Wu W, Wu H, et al
    Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus.
    Gut. 2020 Dec 10. pii: gutjnl-2020-321386. doi: 10.1136/gutjnl-2020-321386.
    PubMed     Abstract available

  19. VILY-PETIT J, Soty-Roca M, Silva M, Raffin M, et al
    Intestinal gluconeogenesis prevents obesity-linked liver steatosis and non-alcoholic fatty liver disease.
    Gut. 2020;69:2193-2202.
    PubMed     Abstract available

    November 2020
  20. SUN N, Shen C, Zhang L, Wu X, et al
    Hepatic Kruppel-like factor 16 (KLF16) targets PPARalpha to improve steatohepatitis and insulin resistance.
    Gut. 2020 Nov 30. pii: gutjnl-2020-321774. doi: 10.1136/gutjnl-2020-321774.
    PubMed     Abstract available

  21. CALDERARO J, Kather JN
    Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers.
    Gut. 2020 Nov 19. pii: gutjnl-2020-322880. doi: 10.1136/gutjnl-2020-322880.
    PubMed     Abstract available

  22. KOH EH, Yoon JE, Ko MS, Leem J, et al
    Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis.
    Gut. 2020 Nov 18. pii: gutjnl-2020-322509. doi: 10.1136/gutjnl-2020-322509.
    PubMed     Abstract available

  23. HAO L, Zhong W, Dong H, Guo W, et al
    ATF4 activation promotes hepatic mitochondrial dysfunction by repressing NRF1-TFAM signalling in alcoholic steatohepatitis.
    Gut. 2020 Nov 11. pii: gutjnl-2020-321548. doi: 10.1136/gutjnl-2020-321548.
    PubMed     Abstract available

    Keeping the liver fit with TREM2 during hepatic carcinogenesis.
    Gut. 2020 Nov 4. pii: gutjnl-2020-322638. doi: 10.1136/gutjnl-2020-322638.

  25. SHANG R, Song X, Wang P, Zhou Y, et al
    Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
    Gut. 2020 Nov 3. pii: gutjnl-2020-320716. doi: 10.1136/gutjnl-2020-320716.
    PubMed     Abstract available

  26. LYU Z, Miao Q, Jiang P, Xiao X, et al
    Unexplained liver dysfunction in a young Chinese man with eosinophilia.
    Gut. 2020;69:1938-1987.

    October 2020
  27. BAYO J, Fiore EJ, Dominguez LM, Cantero MJ, et al
    Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma.
    Gut. 2020 Oct 26. pii: gutjnl-2020-321454. doi: 10.1136/gutjnl-2020-321454.
    PubMed     Abstract available

  28. PRAKTIKNJO M, Schierwagen R, Monteiro S, Ortiz C, et al
    Hepatic inflammasome activation as origin of Interleukin-1alpha and Interleukin-1beta in liver cirrhosis.
    Gut. 2020 Oct 21. pii: gutjnl-2020-322621. doi: 10.1136/gutjnl-2020-322621.

  29. TILG H, Targher G
    NAFLD-related mortality: simple hepatic steatosis is not as 'benign' as thought.
    Gut. 2020 Oct 19. pii: gutjnl-2020-323188. doi: 10.1136/gutjnl-2020-323188.

  30. AITHAL GP, Palaniyappan N, China L, Harmala S, et al
    Guidelines on the management of ascites in cirrhosis.
    Gut. 2020 Oct 16. pii: gutjnl-2020-321790. doi: 10.1136/gutjnl-2020-321790.
    PubMed     Abstract available

  31. TRANAH TH, Edwards LA, Schnabl B, Shawcross DL, et al
    Targeting the gut-liver-immune axis to treat cirrhosis.
    Gut. 2020 Oct 15. pii: gutjnl-2020-320786. doi: 10.1136/gutjnl-2020-320786.
    PubMed     Abstract available

  32. IAVARONE M, D'Ambrosio R, Lampertico P
    Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19.
    Gut. 2020 Oct 7. pii: gutjnl-2020-322929. doi: 10.1136/gutjnl-2020-322929.

  33. ZHANG N, Jiang W, Zhang Y, Song TQ, et al
    Individualised tailored assessment of therapeutic alternatives for HCC patients within the Milan criteria.
    Gut. 2020;69:1893-1895.

  34. DE TONI EN
    Immune checkpoint inhibitors: use them early, combined and instead of TACE?
    Gut. 2020;69:1887-1888.

  35. BASELLI GA, Dongiovanni P, Rametta R, Meroni M, et al
    Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker.
    Gut. 2020;69:1855-1866.
    PubMed     Abstract available

  36. PIRONI L, Steiger E, Joly F, Wanten GJA, et al
    Intravenous supplementation type and volume are associated with 1-year outcome and major complications in patients with chronic intestinal failure.
    Gut. 2020;69:1787-1795.
    PubMed     Abstract available

    September 2020
  37. SHI JY, Wang X, Ding GY, Dong Z, et al
    Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning.
    Gut. 2020 Sep 30. pii: gutjnl-2020-320930. doi: 10.1136/gutjnl-2020-320930.
    PubMed     Abstract available

  38. BAJAJ JS, Sikaroodi M, Shamsaddini A, Henseler Z, et al
    Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
    Gut. 2020 Sep 30. pii: gutjnl-2020-322470. doi: 10.1136/gutjnl-2020-322470.
    PubMed     Abstract available

  39. ESPARZA-BAQUER A, Labiano I, Sharif O, Agirre-Lizaso A, et al
    TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms.
    Gut. 2020 Sep 9. pii: gutjnl-2019-319227. doi: 10.1136/gutjnl-2019-319227.
    PubMed     Abstract available

  40. WU CY, Ho HJ, Wu CY, Chen YJ, et al
    Association between proton pump inhibitor use and mortality in patients with hepatocellular carcinoma receiving tyrosine kinase inhibitor.
    Gut. 2020 Sep 9. pii: gutjnl-2020-321932. doi: 10.1136/gutjnl-2020-321932.

  41. VON FELDEN J, Garcia-Lezana T, Schulze K, Losic B, et al
    Liquid biopsy in the clinical management of hepatocellular carcinoma.
    Gut. 2020 Sep 3. pii: gutjnl-2019-320282. doi: 10.1136/gutjnl-2019-320282.
    PubMed     Abstract available

  42. TARGHER G, Byrne CD, Tilg H
    NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications.
    Gut. 2020;69:1691-1705.
    PubMed     Abstract available

  43. SZAFRON D, Kim HS, Turin CG, Benzi E, et al
    Duodenal and liver lesions in an adult with generalised weakness.
    Gut. 2020;69:1-2.

    August 2020
  44. SHARMA S, Elhence A, Vaishnav M, Kumar R, et al
    COVID-19 in patients with cirrhosis: understanding adverse impact.
    Gut. 2020 Aug 21. pii: gutjnl-2020-322561. doi: 10.1136/gutjnl-2020-322561.

  45. YAMAMOTO A, Kawada N, Jogo A, Murai K, et al
    Utility of minimally invasive measurement of hepatic venous pressure gradient via the peripheral antecubital vein.
    Gut. 2020 Aug 18. pii: gutjnl-2020-322367. doi: 10.1136/gutjnl-2020-322367.

  46. YANG H, Sun L, Mao Y
    Response letter to: letter to the editor: three-dimensional bioprinted hepatorganoids in liver failure.
    Gut. 2020 Aug 14. pii: gutjnl-2020-322471. doi: 10.1136/gutjnl-2020-322471.

  47. PINTER M, Scheiner B, Peck-Radosavljevic M
    Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.
    Gut. 2020 Aug 3. pii: gutjnl-2020-321702. doi: 10.1136/gutjnl-2020-321702.
    PubMed     Abstract available

  48. BOLLIPO S, Kapuria D, Rabiee A, Ben-Yakov G, et al
    One world, one pandemic, many guidelines: management of liver diseases during COVID-19.
    Gut. 2020;69:1369-1372.

  49. TARGHER G, Mantovani A, Byrne CD, Wang XB, et al
    Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.
    Gut. 2020;69:1545-1547.

  50. RADU P, Dufour JF
    Changing TACTICS in intermediate HCC: TACE plus sorafenib.
    Gut. 2020;69:1374-1376.

  51. TILG H, Burcelin R, Tremaroli V
    Liver tissue microbiome in NAFLD: next step in understanding the gut-liver axis?
    Gut. 2020;69:1373-1374.

  52. JOHNSTON M, Cook C, Buchanan RM
    RE: Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial.
    Gut. 2020;69:1536-1537.

    July 2020
  53. KAUR S, Tripathi DM, Ghosh S
    Three-dimensional bioprinted hepatorganoids in liver failure.
    Gut. 2020 Jul 21. pii: gutjnl-2020-322317. doi: 10.1136/gutjnl-2020-322317.

  54. BAJAJ JS, Garcia-Tsao G, Biggins S, Kamath PS, et al
    Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort.
    Gut. 2020 Jul 13. pii: gutjnl-2020-322118. doi: 10.1136/gutjnl-2020-322118.
    PubMed     Abstract available

  55. WEBER S, Mayerle J, Irlbeck M, Gerbes AL, et al
    Severe liver failure during SARS-CoV-2 infection.
    Gut. 2020;69:1365-1367.

  56. GEIER A, Boursier J
    Non-invasive diagnosis of patients with 'at-risk' NAFLD : only fibrosis counts?
    Gut. 2020;69:1164-1165.

    June 2020
  57. CARGILL Z, Brown SE, Dusheiko G, Agarwal K, et al
    Risk stratification in chronic hepatitis B patients for hepatocellular carcinoma surveillance: management in migrant sub-Saharan African populations.
    Gut. 2020 Jun 30. pii: gutjnl-2020-322181. doi: 10.1136/gutjnl-2020-322181.

  58. THANGAPANDI VR, Knittelfelder O, Brosch M, Patsenker E, et al
    Loss of hepatic Mboat7 leads to liver fibrosis.
    Gut. 2020 Jun 26. pii: gutjnl-2020-320853. doi: 10.1136/gutjnl-2020-320853.
    PubMed     Abstract available

  59. STENGEL S, Steube A, Kose-Vogel N, Kirchberger-Tolstik T, et al
    Primed circulating monocytes are a source of IL-1beta in patients with cirrhosis and ascites.
    Gut. 2020 Jun 22. pii: gutjnl-2020-321597. doi: 10.1136/gutjnl-2020-321597.

  60. BECCHETTI C, Zambelli MF, Pasulo L, Donato MF, et al
    COVID-19 in an international European liver transplant recipient cohort.
    Gut. 2020 Jun 22. pii: gutjnl-2020-321923. doi: 10.1136/gutjnl-2020-321923.
    PubMed     Abstract available

    Harnessing liver progenitors in the treatment of liver fibrosis: a step in the right direction?
    Gut. 2020;69:975-976.

  62. BAYARD Q, Nault JC, Zucman-Rossi J
    RSPO2 abnormal transcripts result from read-through in liver tumours with high ss-catenin activation and CTNNB1 mutations.
    Gut. 2020;69:1152-1153.

  63. DAI Z, Song G, Balakrishnan A, Yang T, et al
    Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells.
    Gut. 2020;69:1104-1115.
    PubMed     Abstract available

  64. WANG Y, Wong GL, He FP, Sun J, et al
    Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy.
    Gut. 2020;69:1116-1126.
    PubMed     Abstract available

    May 2020
  65. QI X, Liu Y, Wang J, Fallowfield J, et al
    Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
    Gut. 2020 May 20. pii: gutjnl-2020-321666. doi: 10.1136/gutjnl-2020-321666.

  66. YANG H, Sun L, Pang Y, Hu D, et al
    Three-dimensional bioprinted hepatorganoids prolong survival of mice with liver failure.
    Gut. 2020 May 20. pii: gutjnl-2019-319960. doi: 10.1136/gutjnl-2019-319960.
    PubMed     Abstract available

  67. NATHANI P, Gopal P, Rich N, Yopp A, et al
    Hepatocellular carcinoma tumour volume doubling time: a systemic review and meta-analysis.
    Gut. 2020 May 12. pii: gutjnl-2020-321040. doi: 10.1136/gutjnl-2020-321040.
    PubMed     Abstract available

  68. DUFOUR JF, Caussy C, Loomba R
    Combination for therapy non-alcoholic steatohepatitis: rationale, opportunities and challenges.
    Gut. 2020 May 7. pii: gutjnl-2019-319104. doi: 10.1136/gutjnl-2019-319104.
    PubMed     Abstract available

    April 2020
  69. DE JONG YP, Liang TJ
    Stem cell-derived HCV infection systems illustrate the bright future of human hepatocyte research.
    Gut. 2020 Apr 29. pii: gutjnl-2020-321216. doi: 10.1136/gutjnl-2020-321216.

  70. MONTEIRO S, Grandt J, Uschner FE, Kimer N, et al
    Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation.
    Gut. 2020 Apr 2. pii: gutjnl-2019-320170. doi: 10.1136/gutjnl-2019-320170.
    PubMed     Abstract available

  71. CINNAMON E, Pikarsky E
    Are we ready for targeted therapy combinations in HCC?
    Gut. 2020;69:613-614.

  72. AVILA MA, Dufour JF, Gerbes AL, Zoulim F, et al
    Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting.
    Gut. 2020;69:764-780.
    PubMed     Abstract available

  73. LA BELLA T, Imbeaud S, Peneau C, Mami I, et al
    Adeno-associated virus in the liver: natural history and consequences in tumour development.
    Gut. 2020;69:737-747.
    PubMed     Abstract available

  74. NATHWANI R, Mullish BH, Kockerling D, Rajani N, et al
    Recurrent bacteraemia following variceal haemorrhage.
    Gut. 2020;69:726-780.

    March 2020
  75. SU F, Ioannou GN, Berry K
    No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
    Gut. 2020 Mar 30. pii: gutjnl-2019-319867. doi: 10.1136/gutjnl-2019-319867.
    PubMed     Abstract available

  76. HUTCHINSON SJ, Valerio H, McDonald SA, Yeung A, et al
    Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Gut. 2020 Mar 26. pii: gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007.
    PubMed     Abstract available

  77. JUHLING F, Hamdane N, Crouchet E, Li S, et al
    Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma.
    Gut. 2020 Mar 26. pii: gutjnl-2019-318918. doi: 10.1136/gutjnl-2019-318918.
    PubMed     Abstract available

    Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit.
    Gut. 2020 Mar 23. pii: gutjnl-2019-320355. doi: 10.1136/gutjnl-2019-320355.

  79. BOSCH J, Gracia-Sancho J, Abraldes JG
    Cirrhosis as new indication for statins.
    Gut. 2020 Mar 5. pii: gutjnl-2019-318237. doi: 10.1136/gutjnl-2019-318237.
    PubMed     Abstract available

    February 2020
  80. CARPENTIER A, Sheldon J, Vondran FWR, Brown RJ, et al
    Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus.
    Gut. 2020 Feb 29. pii: gutjnl-2019-319354. doi: 10.1136/gutjnl-2019-319354.
    PubMed     Abstract available

  81. TRIPATHI D, Stanley AJ, Hayes PC, Travis S, et al
    Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension.
    Gut. 2020 Feb 29. pii: gutjnl-2019-320221. doi: 10.1136/gutjnl-2019-320221.
    PubMed     Abstract available

  82. SALERNO D, Chiodo L, Alfano V, Floriot O, et al
    Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription.
    Gut. 2020 Feb 29. pii: gutjnl-2019-319637. doi: 10.1136/gutjnl-2019-319637.
    PubMed     Abstract available

  83. BERNARDI M, Angeli P, Claria J, Moreau R, et al
    Albumin in decompensated cirrhosis: new concepts and perspectives.
    Gut. 2020 Feb 26. pii: gutjnl-2019-318843. doi: 10.1136/gutjnl-2019-318843.
    PubMed     Abstract available

  84. LOOMBA R, Adams LA
    Advances in non-invasive assessment of hepatic fibrosis.
    Gut. 2020 Feb 17. pii: gutjnl-2018-317593. doi: 10.1136/gutjnl-2018-317593.
    PubMed     Abstract available

  85. DE TONI EN, Roessler D
    Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma.
    Gut. 2020 Feb 12. pii: gutjnl-2020-320604. doi: 10.1136/gutjnl-2020-320604.

  86. KAMAL F, Khan MA, Ahmed A, Nair S, et al
    Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B.
    Gut. 2020 Feb 10. pii: gutjnl-2019-320554. doi: 10.1136/gutjnl-2019-320554.

  87. SHEN J, Chen M, Lee D, Law CT, et al
    Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression.
    Gut. 2020;69:329-342.
    PubMed     Abstract available

  88. BOU-NADER M, Caruso S, Donne R, Celton-Morizur S, et al
    Polyploidy spectrum: a new marker in HCC classification.
    Gut. 2020;69:355-364.
    PubMed     Abstract available

    January 2020
  89. DROPMANN A, Dooley S, Dewidar B, Hammad S, et al
    TGF-beta2 silencing to target biliary-derived liver diseases.
    Gut. 2020 Jan 28. pii: gutjnl-2019-319091. doi: 10.1136/gutjnl-2019-319091.
    PubMed     Abstract available

  90. SOBOLEWSKI C, Abegg D, Berthou F, Dolicka D, et al
    S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development.
    Gut. 2020 Jan 9. pii: gutjnl-2019-319019. doi: 10.1136/gutjnl-2019-319019.
    PubMed     Abstract available

  91. BAYARD Q, Caruso S, Couchy G, Rebouissou S, et al
    Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas.
    Gut. 2020 Jan 6. pii: gutjnl-2019-319790. doi: 10.1136/gutjnl-2019-319790.
    PubMed     Abstract available

  92. SOOKOIAN S, Salatino A, Castano GO, Landa MS, et al
    Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease.
    Gut. 2020 Jan 2. pii: gutjnl-2019-318811. doi: 10.1136/gutjnl-2019-318811.
    PubMed     Abstract available

  93. Correction: Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma.
    Gut. 2020;69:e1.

  94. VUCUR M, Luedde T
    Life is fragile: FMRP controls cell death in liver disease.
    Gut. 2020;69:2-3.

    December 2019
  95. CAI J, Zhang Z, He C, Zhang W, et al
    Reply to 'Are the 5-hydroxymethylcytosine-based wd-scores really superior over alpha-fetoprotein for the early diagnosis of hepatocellular carcinoma?'
    Gut. 2019 Dec 23. pii: gutjnl-2019-320298. doi: 10.1136/gutjnl-2019-320298.

  96. FENG Z, Rong P, Wang W
    Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma.
    Gut. 2019 Dec 18. pii: gutjnl-2019-320116. doi: 10.1136/gutjnl-2019-320116.

  97. TENG YX, Li MJ, Xiang BD, Zhong JH, et al
    Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis.
    Gut. 2019 Dec 16. pii: gutjnl-2019-320326. doi: 10.1136/gutjnl-2019-320326.

  98. HARMS MH, de Veer RC, Lammers WJ, Corpechot C, et al
    Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Gut. 2019 Dec 16. pii: gutjnl-2019-319057. doi: 10.1136/gutjnl-2019-319057.
    PubMed     Abstract available

  99. KUDO M, Ueshima K, Ikeda M, Torimura T, et al
    Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
    Gut. 2019 Dec 4. pii: gutjnl-2019-318934. doi: 10.1136/gutjnl-2019-318934.
    PubMed     Abstract available

  100. JOOSSENS M, Faust K, Gryp T, Nguyen ATL, et al
    Gut microbiota dynamics and uraemic toxins: one size does not fit all.
    Gut. 2019;68:2257-2260.

    November 2019
  101. LING S, Shan Q, Zhan Q, Ye Q, et al
    USP22 promotes hypoxia-induced hepatocellular carcinoma stemness by a HIF1alpha/USP22 positive feedback loop upon TP53 inactivation.
    Gut. 2019 Nov 27. pii: gutjnl-2019-319616. doi: 10.1136/gutjnl-2019-319616.
    PubMed     Abstract available

  102. XU WP, Liu JP, Feng JF, Zhu CP, et al
    miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
    Gut. 2019 Nov 14. pii: gutjnl-2019-318830. doi: 10.1136/gutjnl-2019-318830.
    PubMed     Abstract available

  103. JOHN M, Kim KJ, Bae SDW, Qiao L, et al
    Role of BMP-9 in human liver disease.
    Gut. 2019;68:2097-2100.

  104. GJORGJIEVA M, Sobolewski C, Dolicka D, Correia de Sousa M, et al
    miRNAs and NAFLD: from pathophysiology to therapy.
    Gut. 2019;68:2065-2079.
    PubMed     Abstract available

  105. WONG VW, Irles M, Wong GL, Shili S, et al
    Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease.
    Gut. 2019;68:2057-2064.
    PubMed     Abstract available

    October 2019
  106. LEE SW, Kwon JH, Lee HL, Yoo SH, et al
    Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
    Gut. 2019 Oct 31. pii: gutjnl-2019-318947. doi: 10.1136/gutjnl-2019-318947.
    PubMed     Abstract available

  107. CHEN Y, Lin XY
    Are the 5-hydroxymethylcytosine-based wd-scores really superior over alpha-fetoprotein for the early diagnosis of hepatocellular carcinoma?
    Gut. 2019 Oct 25. pii: gutjnl-2019-319853. doi: 10.1136/gutjnl-2019-319853.

  108. FOGLIA B, Parola M
    Of FACT complex and oxidative stress response: a KEAP1/NRF2-dependent novel mechanism sustaining hepatocellular carcinoma progression.
    Gut. 2019 Oct 15. pii: gutjnl-2019-319609. doi: 10.1136/gutjnl-2019-319609.

  109. WANG D, Li X, Li J, Lu Y, et al
    APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression.
    Gut. 2019;68:1846-1857.
    PubMed     Abstract available

  110. KORF H, du Plessis J, van Pelt J, De Groote S, et al
    Inhibition of glutamine synthetase in monocytes from patients with acute-on-chronic liver failure resuscitates their antibacterial and inflammatory capacity.
    Gut. 2019;68:1872-1883.
    PubMed     Abstract available

  111. CAUSSY C, Ajmera VH, Puri P, Hsu CL, et al
    Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.
    Gut. 2019;68:1884-1892.
    PubMed     Abstract available

    September 2019
  112. MARTI-RODRIGO A, Alegre F, Moragrega AB, Garcia-Garcia F, et al
    Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells.
    Gut. 2019 Sep 17. pii: gutjnl-2019-318372. doi: 10.1136/gutjnl-2019-318372.
    PubMed     Abstract available

  113. WANG C, Wang H, Lieftink C, du Chatinier A, et al
    CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
    Gut. 2019 Sep 13. pii: gutjnl-2019-318506. doi: 10.1136/gutjnl-2019-318506.
    PubMed     Abstract available

  114. CHANG Y, Ryu S, Sung KC, Cho YK, et al
    Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study.
    Gut. 2019;68:1667-1675.
    PubMed     Abstract available

    August 2019
    New warning signs on the road: 5-hydroxymethylcytosine-based liquid biopsy for the early detection of hepatocellular carcinoma.
    Gut. 2019 Aug 7. pii: gutjnl-2019-319339. doi: 10.1136/gutjnl-2019-319339.

  116. SAROBE P, Corrales F
    Getting insights into hepatocellular carcinoma tumour heterogeneity by multiomics dissection.
    Gut. 2019 Aug 2. pii: gutjnl-2019-319410. doi: 10.1136/gutjnl-2019-319410.

  117. HENDRIKX T, Duan Y, Wang Y, Oh JH, et al
    Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice.
    Gut. 2019;68:1504-1515.
    PubMed     Abstract available

    July 2019
  118. CAI J, Chen L, Zhang Z, Zhang X, et al
    Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma.
    Gut. 2019 Jul 29. pii: gutjnl-2019-318882. doi: 10.1136/gutjnl-2019-318882.
    PubMed     Abstract available

  119. GUERRA MT, Florentino RM, Franca A, Lima Filho AC, et al
    Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma.
    Gut. 2019 Jul 17. pii: gutjnl-2018-317811. doi: 10.1136/gutjnl-2018-317811.
    PubMed     Abstract available

  120. KIM DH, Choi SH, Park SH, Kim KW, et al
    Meta-analysis of the accuracy of Liver Imaging Reporting and Data System category 4 or 5 for diagnosing hepatocellular carcinoma.
    Gut. 2019 Jul 12. pii: gutjnl-2019-318555. doi: 10.1136/gutjnl-2019-318555.

  121. QUECK A, Carnevale R, Uschner FE, Schierwagen R, et al
    Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS.
    Gut. 2019 Jul 3. pii: gutjnl-2019-319044. doi: 10.1136/gutjnl-2019-319044.

  122. MUSSO O, Beraza N
    Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor.
    Gut. 2019 Jul 3. pii: gutjnl-2019-318999. doi: 10.1136/gutjnl-2019-318999.

  123. Correction: Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis.
    Gut. 2019;68:1342.

  124. LONGERICH T, Endris V, Neumann O, Rempel E, et al
    RSPO2 gene rearrangement: a powerful driver of beta-catenin activation in liver tumours.
    Gut. 2019;68:1287-1296.
    PubMed     Abstract available

  125. BERRAONDO P, Martini PGV, Avila MA, Fontanellas A, et al
    Messenger RNA therapy for rare genetic metabolic diseases.
    Gut. 2019;68:1323-1330.
    PubMed     Abstract available

    June 2019
    Epigenetic modulation of immunity: towards new therapeutic avenues in hepatocellular carcinoma?
    Gut. 2019 Jun 26. pii: gutjnl-2019-319084. doi: 10.1136/gutjnl-2019-319084.

  127. ZHANG Q, Lou Y, Yang J, Wang J, et al
    Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas.
    Gut. 2019 Jun 21. pii: gutjnl-2019-318912. doi: 10.1136/gutjnl-2019-318912.
    PubMed     Abstract available

  128. TAO L, Ma W, Wu L, Xu M, et al
    Glial cell line-derived neurotrophic factor (GDNF) mediates hepatic stellate cell activation via ALK5/Smad signalling.
    Gut. 2019 Jun 6. pii: gutjnl-2018-317872. doi: 10.1136/gutjnl-2018-317872.
    PubMed     Abstract available

  129. MITCHELL J, O'Beirne J
    Benefit of haemostatic spray in variceal bleeding: early application of spray or early application of guidelines?
    Gut. 2019;68:1134-1135.

  130. HYUN J, Oh SH, Premont RT, Guy CD, et al
    Dysregulated activation of fetal liver programme in acute liver failure.
    Gut. 2019;68:1076-1087.
    PubMed     Abstract available

  131. PINYOL R, Montal R, Bassaganyas L, Sia D, et al
    Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
    Gut. 2019;68:1065-1075.
    PubMed     Abstract available

  132. ALFERINK LJ, Kiefte-de Jong JC, Erler NS, Veldt BJ, et al
    Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study.
    Gut. 2019;68:1088-1098.
    PubMed     Abstract available

    May 2019
  133. XIANG DM, Sun W, Zhou T, Zhang C, et al
    Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance.
    Gut. 2019 May 22. pii: gutjnl-2018-317440. doi: 10.1136/gutjnl-2018-317440.
    PubMed     Abstract available

  134. DOHAN A, Gallix B, Guiu B, Le Malicot K, et al
    Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Gut. 2019 May 17. pii: gutjnl-2018-316407. doi: 10.1136/gutjnl-2018-316407.
    PubMed     Abstract available

  135. KRENKEL O, Hundertmark J, Abdallah AT, Kohlhepp M, et al
    Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis.
    Gut. 2019 May 10. pii: gutjnl-2019-318382. doi: 10.1136/gutjnl-2019-318382.
    PubMed     Abstract available

  136. LIU M, Zhou J, Liu X, Feng Y, et al
    Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Gut. 2019 May 10. pii: gutjnl-2018-317257. doi: 10.1136/gutjnl-2018-317257.
    PubMed     Abstract available

  137. RUIZ DE GALARRETA M, Lujambio A
    Hepatocellular carcinoma: killing one bird with two stones.
    Gut. 2019 May 10. pii: gutjnl-2019-318649. doi: 10.1136/gutjnl-2019-318649.

  138. IBRAHIM M, El-Mikkawy A, Abdel Hamid M, Abdalla H, et al
    Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial.
    Gut. 2019;68:844-853.
    PubMed     Abstract available

    April 2019
  139. SINGHI AD, Nikiforova MN, Chennat J, Papachristou GI, et al
    Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures.
    Gut. 2019 Apr 10. pii: gutjnl-2018-317817. doi: 10.1136/gutjnl-2018-317817.
    PubMed     Abstract available

    Hepatocellular adenomas: one step beyond.
    Gut. 2019 Apr 9. pii: gutjnl-2019-318299. doi: 10.1136/gutjnl-2019-318299.

  141. CHE L, Chi W, Qiao Y, Zhang J, et al
    Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
    Gut. 2019 Apr 6. pii: gutjnl-2018-317581. doi: 10.1136/gutjnl-2018-317581.
    PubMed     Abstract available

    March 2019
  142. ZHU Y, Yang J, Xu D, Gao XM, et al
    Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Gut. 2019 Mar 22. pii: gutjnl-2019-318419. doi: 10.1136/gutjnl-2019-318419.
    PubMed     Abstract available

  143. CUBERO FJ, Martinez-Chantar ML
    Plasticity of adult hepatocytes and readjustment of cell fate: a novel dogma in liver disease.
    Gut. 2019 Mar 18. pii: gutjnl-2019-318218. doi: 10.1136/gutjnl-2019-318218.

  144. DE TONI EN, Schlesinger-Raab A, Fuchs M, Schepp W, et al
    Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study.
    Gut. 2019 Mar 16. pii: gutjnl-2018-318193. doi: 10.1136/gutjnl-2018-318193.
    PubMed     Abstract available

  145. KASPER P, Goeser T, Nierhoff D
    Oesophageal and scaly skin lesions associated with chronic cholestatic liver disease.
    Gut. 2019 Mar 16. pii: gutjnl-2019-318502. doi: 10.1136/gutjnl-2019-318502.

    February 2019
  146. MERLEN G, Kahale N, Ursic-Bedoya J, Bidault-Jourdainne V, et al
    TGR5-dependent hepatoprotection through the regulation of biliary epithelium barrier function.
    Gut. 2019 Feb 5. pii: gutjnl-2018-316975. doi: 10.1136/gutjnl-2018-316975.
    PubMed     Abstract available

  147. CHU H, Duan Y, Yang L, Schnabl B, et al
    Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
    Gut. 2019;68:359-370.
    PubMed     Abstract available

    January 2019
  148. YUAN L, Jiang J, Liu X, Zhang Y, et al
    HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation.
    Gut. 2019 Jan 30. pii: gutjnl-2018-316091. doi: 10.1136/gutjnl-2018-316091.
    PubMed     Abstract available

    December 2018
  149. MANN J, Reeves HL, Feldstein AE
    Liquid biopsy for liver diseases.
    Gut. 2018;67:2204-2212.
    PubMed     Abstract available

  150. JAVARY J, Allain-Courtois N, Saucisse N, Costet P, et al
    Liver Reptin/RUVBL2 controls glucose and lipid metabolism with opposite actions on mTORC1 and mTORC2 signalling.
    Gut. 2018;67:2192-2203.
    PubMed     Abstract available

  151. LI M, Xu C, Shi J, Ding J, et al
    Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway.
    Gut. 2018;67:2169-2180.
    PubMed     Abstract available

    November 2018
  152. GILL US, Pallett LJ, Thomas N, Burton AR, et al
    Fine needle aspirates comprehensively sample intrahepatic immunity.
    Gut. 2018 Nov 28. pii: gutjnl-2018-317071. doi: 10.1136/gutjnl-2018-317071.
    PubMed     Abstract available

  153. ALFERINK LJM, Kiefte-de Jong JC, Darwish Murad S
    Animal protein intake and hepatic steatosis in the elderly: authors' response.
    Gut. 2018 Nov 21. pii: gutjnl-2018-317843. doi: 10.1136/gutjnl-2018-317843.

  154. LV Y, Zuo L, Zhu X, Zhao J, et al
    Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study.
    Gut. 2018 Nov 10. pii: gutjnl-2018-317057. doi: 10.1136/gutjnl-2018-317057.
    PubMed     Abstract available

  155. CHEN Q, Shu C, Laurence AD, Chen Y, et al
    Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial.
    Gut. 2018;67:2006-2016.
    PubMed     Abstract available

    October 2018
  156. TANG GY, Mann JP
    Animal protein intake and hepatic steatosis in the elderly.
    Gut. 2018 Oct 30. pii: gutjnl-2018-317709. doi: 10.1136/gutjnl-2018-317709.

  157. ZHAO Y, Shuen TWH, Toh TB, Chan XY, et al
    Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.
    Gut. 2018;67:1845-1854.
    PubMed     Abstract available

  158. FERNANDEZ J, Acevedo J, Wiest R, Gustot T, et al
    Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis.
    Gut. 2018;67:1870-1880.
    PubMed     Abstract available

    September 2018
  159. KREMER AE, Le Cleac'h A, Lemoinne S, Wolf K, et al
    Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis.
    Gut. 2018 Sep 18. pii: gutjnl-2018-317426. doi: 10.1136/gutjnl-2018-317426.

  160. CANI PD
    Human gut microbiome: hopes, threats and promises.
    Gut. 2018;67:1716-1725.
    PubMed     Abstract available

    August 2018
  161. MONTAGNER A, Le Cam L, Guillou H
    beta-catenin oncogenic activation rewires fatty acid catabolism to fuel hepatocellular carcinoma.
    Gut. 2018 Aug 4. pii: gutjnl-2018-316557. doi: 10.1136/gutjnl-2018-316557.

    Lipid-rich environment: a key role promoting carcinogenesis in obesity-related non-alcoholic fatty liver disease.
    Gut. 2018;67:1376-1377.

  163. FUJIWARA N, Nakagawa H, Enooku K, Kudo Y, et al
    CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.
    Gut. 2018;67:1493-1504.
    PubMed     Abstract available

  164. STRNAD P, Buch S, Hamesch K, Fischer J, et al
    Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis.
    Gut. 2018 Aug 1. pii: gutjnl-2018-316228. doi: 10.1136/gutjnl-2018-316228.
    PubMed     Abstract available

    July 2018
  165. REN Z, Li A, Jiang J, Zhou L, et al
    Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.
    Gut. 2018 Jul 25. pii: gutjnl-2017-315084. doi: 10.1136/gutjnl-2017-315084.
    PubMed     Abstract available

  166. LIM CJ, Lee YH, Pan L, Lai L, et al
    Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Gut. 2018 Jul 3. pii: gutjnl-2018-316510. doi: 10.1136/gutjnl-2018-316510.
    PubMed     Abstract available

  167. ROTMAN Y, Sanyal AJ
    Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus-authors' response.
    Gut. 2018;67:1372.

  168. CUSI K
    Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus.
    Gut. 2018;67:1371.

    June 2018
  169. BERNSMEIER C, Triantafyllou E, Brenig R, Lebosse FJ, et al
    CD14(+) CD15(-) HLA-DR(-) myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure.
    Gut. 2018;67:1155-1167.
    PubMed     Abstract available

    May 2018
  170. GRETEN TF, Korangy F
    CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC.
    Gut. 2018;67:783-784.

  171. GAO B, Ma J, Xiang X
    MAIT cells: a novel therapeutic target for alcoholic liver disease?
    Gut. 2018;67:784-786.

  172. RIVA A, Patel V, Kurioka A, Jeffery HC, et al
    Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease.
    Gut. 2018;67:918-930.
    PubMed     Abstract available

  173. GRANDER C, Adolph TE, Wieser V, Lowe P, et al
    Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease.
    Gut. 2018;67:891-901.
    PubMed     Abstract available

    April 2018
  174. SENNI N, Savall M, Cabrerizo Granados D, Alves-Guerra MC, et al
    beta-catenin-activated hepatocellular carcinomas are addicted to fatty acids.
    Gut. 2018 Apr 12. pii: gutjnl-2017-315448. doi: 10.1136/gutjnl-2017-315448.
    PubMed     Abstract available

  175. Correction: Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis.
    Gut. 2018;67:782.

    March 2018
  176. HIRSCHFIELD GM, Dyson JK, Alexander GJM, Chapman MH, et al
    The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
    Gut. 2018 Mar 28. pii: gutjnl-2017-315259. doi: 10.1136/gutjnl-2017-315259.
    PubMed     Abstract available

  177. MAURER MH
    Diagnosis of hepatocellular carcinoma with MRI.
    Gut. 2018 Mar 16. pii: gutjnl-2018-315999. doi: 10.1136/gutjnl-2018-315999.

  178. LIN HH, Tseng TC, Kao JH
    Large and middle hepatitis B surface antigen: the lower the better?
    Gut. 2018 Mar 7. pii: gutjnl-2018-316030. doi: 10.1136/gutjnl-2018-316030.

  179. Correction: Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.
    Gut. 2018;67:594.

  180. LUETKENS JA, Klein S, Traeber F, Schmeel FC, et al
    Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study.
    Gut. 2018;67:593-594.

  181. HESSMANN E, Patzak MS, Klein L, Chen N, et al
    Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.
    Gut. 2018;67:497-507.
    PubMed     Abstract available

  182. SAMSON A, Bentham MJ, Scott K, Nuovo G, et al
    Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.
    Gut. 2018;67:562-573.
    PubMed     Abstract available

    February 2018
  183. HEO MJ, Kim TH, You JS, Blaya D, et al
    Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression.
    Gut. 2018 Feb 23. pii: gutjnl-2017-315123. doi: 10.1136/gutjnl-2017-315123.
    PubMed     Abstract available

  184. CHEW V, Lee YH, Pan L, Nasir NJM, et al
    Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma.
    Gut. 2018 Feb 13. pii: gutjnl-2017-315485. doi: 10.1136/gutjnl-2017-315485.
    PubMed     Abstract available

  185. RENZULLI M, Biselli M, Brocchi S, Granito A, et al
    New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm.
    Gut. 2018 Feb 3. pii: gutjnl-2017-315384. doi: 10.1136/gutjnl-2017-315384.
    PubMed     Abstract available

  186. LEE JH, Suh JH, Choi SY, Kang HJ, et al
    Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis.
    Gut. 2018 Feb 2. pii: gutjnl-2017-315348. doi: 10.1136/gutjnl-2017-315348.
    PubMed     Abstract available

  187. PUENGEL T, Tacke F
    Repair macrophages in acute liver failure.
    Gut. 2018;67:202-203.

  188. EFERL R, Trauner M
    Chromosomal instability in HCC: a key function for checkpoint kinase 2.
    Gut. 2018;67:204-205.

    January 2018
  189. PERUGORRIA MJ, Esparza-Baquer A, Oakley F, Labiano I, et al
    Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage.
    Gut. 2018 Jan 27. pii: gutjnl-2017-314107. doi: 10.1136/gutjnl-2017-314107.
    PubMed     Abstract available

  190. IBRAHIM SH, Hirsova P, Gores GJ
    Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315691. doi: 10.1136/gutjnl-2017-315691.
    PubMed     Abstract available

  191. CHEN CJ
    Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315407. doi: 10.1136/gutjnl-2017-315407.

  192. BANTEL H, Canbay A
    Loss of KRAS control as consequence of downregulated microRNA-622 in hepatocellular carcinoma and its potential therapeutic implication.
    Gut. 2018 Jan 20. pii: gutjnl-2017-315630. doi: 10.1136/gutjnl-2017-315630.

  193. YIGIT B, Boyle M, Ozler O, Erden N, et al
    Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis.
    Gut. 2018 Jan 20. pii: gutjnl-2017-315668. doi: 10.1136/gutjnl-2017-315668.

  194. PERNES G, Lancaster GI, Murphy AJ
    Take me to the liver: adipose tissue macrophages coordinate hepatic neutrophil recruitment.
    Gut. 2018 Jan 3. pii: gutjnl-2017-315393. doi: 10.1136/gutjnl-2017-315393.

  195. NEWSOME PN, Cramb R, Davison SM, Dillon JF, et al
    Guidelines on the management of abnormal liver blood tests.
    Gut. 2018;67:6-19.
    PubMed     Abstract available

  196. WIESER V, Adolph TE, Grander C, Grabherr F, et al
    Adipose type I interferon signalling protects against metabolic dysfunction.
    Gut. 2018;67:157-165.
    PubMed     Abstract available

    December 2017
  197. DIETRICH P, Koch A, Fritz V, Hartmann A, et al
    Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
    Gut. 2017 Dec 23. pii: gutjnl-2017-315402. doi: 10.1136/gutjnl-2017-315402.
    PubMed     Abstract available

  198. CUI CP, Wong CC, Kai AK, Ho DW, et al
    SENP1 promotes hypoxia-induced cancer stemness by HIF-1alpha deSUMOylation and SENP1/HIF-1alpha positive feedback loop.
    Gut. 2017;66:2149-2159.
    PubMed     Abstract available

  199. CONIGLIARO A, Tripodi M, Parola M
    SENP1 activity sustains cancer stem cell in hypoxic HCC.
    Gut. 2017;66:2051-2052.

    November 2017
  200. GERBES A, Zoulim F, Tilg H, Dufour JF, et al
    Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.
    Gut. 2017 Nov 17. pii: gutjnl-2017-315068. doi: 10.1136/gutjnl-2017-315068.
    PubMed     Abstract available

    October 2017
  201. MAZARD T, Boonsirikamchai P, Overman MJ, Asran MA, et al
    Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
    Gut. 2017 Oct 30. pii: gutjnl-2017-313786. doi: 10.1136/gutjnl-2017-313786.
    PubMed     Abstract available

  202. BIJNEN M, Josefs T, Cuijpers I, Maalsen CJ, et al
    Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice.
    Gut. 2017 Oct 26. pii: gutjnl-2016-313654. doi: 10.1136/gutjnl-2016-313654.
    PubMed     Abstract available

  203. KIM GA, Lim YS, Han S, Choi J, et al
    High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Gut. 2017 Oct 21. pii: gutjnl-2017-314904. doi: 10.1136/gutjnl-2017-314904.
    PubMed     Abstract available

  204. BROWN PM, Rotman Y
    What if Prometheus had steatosis? Potential use of FGF19 to promote regeneration of the fatty liver.
    Gut. 2017;66:1732-1733.

    September 2017
  205. LV Y, Qi X, He C, Wang Z, et al
    Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial.
    Gut. 2017 Sep 28. pii: gutjnl-2017-314634. doi: 10.1136/gutjnl-2017-314634.
    PubMed     Abstract available

  206. ZHOU J, Liu M, Sun H, Feng Y, et al
    Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
    Gut. 2017 Sep 22. pii: gutjnl-2017-314032. doi: 10.1136/gutjnl-2017-314032.
    PubMed     Abstract available

  207. MUELLER C, Waldburger N, Stampfl U, Kauczor HU, et al
    Non-invasive diagnosis of hepatocellular carcinoma revisited.
    Gut. 2017 Sep 12. pii: gutjnl-2017-314981. doi: 10.1136/gutjnl-2017-314981.

  208. KIM W, Khan SK, Liu Y, Xu R, et al
    Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma.
    Gut. 2017 Sep 2. pii: gutjnl-2017-314061. doi: 10.1136/gutjnl-2017-314061.
    PubMed     Abstract available

  209. Erratum: The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Gut. 2017;66:1730.

  210. BEDOSSA P, Tordjman J, Aron-Wisnewsky J, Poitou C, et al
    Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity.
    Gut. 2017;66:1688-1696.
    PubMed     Abstract available

  211. MAGDALENO F, Trebicka J
    Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression.
    Gut. 2017;66:1540-1541.

    August 2017
  212. PIANO S, Bartoletti M, Tonon M, Baldassarre M, et al
    Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections.
    Gut. 2017 Aug 31. pii: gutjnl-2017-314324. doi: 10.1136/gutjnl-2017-314324.
    PubMed     Abstract available

  213. JIAO N, Baker SS, Chapa-Rodriguez A, Liu W, et al
    Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.
    Gut. 2017 Aug 3. pii: gutjnl-2017-314307. doi: 10.1136/gutjnl-2017-314307.
    PubMed     Abstract available

  214. HO DWH, Chan LK, Chiu YT, Xu IMJ, et al
    TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication.
    Gut. 2017;66:1496-1506.
    PubMed     Abstract available

  215. BERASAIN C, Lechel A
    Targeting the correct target in HCC.
    Gut. 2017;66:1352-1354.

    July 2017
  216. XIANG DM, Sun W, Ning BF, Zhou TF, et al
    The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis.
    Gut. 2017 Jul 28. pii: gutjnl-2016-313392. doi: 10.1136/gutjnl-2016-313392.
    PubMed     Abstract available

  217. CORRAL JE, Mousa OY, Riegert-Johnson DL
    Massive gastrointestinal bleeding after transjugular intrahepatic portosystemic shunt (TIPS).
    Gut. 2017 Jul 7. pii: gutjnl-2017-314254. doi: 10.1136/gutjnl-2017-314254.

  218. ALBANO E, Stickel F
    Targeting toll-like receptor 7/8 improves host anti-infective response in alcoholic cirrhosis.
    Gut. 2017 Jul 7. pii: gutjnl-2017-314437. doi: 10.1136/gutjnl-2017-314437.

  219. HARDY T, Zeybel M, Day CP, Dipper C, et al
    Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.
    Gut. 2017;66:1321-1328.
    PubMed     Abstract available

  220. CALVISI D, Eferl R
    CDK4/6 inhibition and sorafenib: a menage a deux in HCC therapy?
    Gut. 2017;66:1179-1180.

  221. MANDORFER M, Peck-Radosavljevic M, Reiberger T
    Prevention of progression from small to large varices: are we there yet? An updated meta-analysis.
    Gut. 2017;66:1347-1349.

    June 2017
  222. ROLAS L, Boussif A, Weiss E, Letteron P, et al
    NADPH oxidase depletion in neutrophils from patients with cirrhosis and restoration via toll-like receptor 7/8 activation.
    Gut. 2017 Jun 10. pii: gutjnl-2016-313443. doi: 10.1136/gutjnl-2016-313443.
    PubMed     Abstract available

  223. JIANG RY, Yang L
    The role of hepatokines in NAFLD-related extrahepatic diseases: culprit or accomplice?
    Gut. 2017 Jun 10. pii: gutjnl-2017-314411. doi: 10.1136/gutjnl-2017-314411.

  224. LYU N, Lin Y, Kong Y, Zhang Z, et al
    FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut. 2017 Jun 7. pii: gutjnl-2017-314138. doi: 10.1136/gutjnl-2017-314138.

  225. WANG Z, Zhang H, Han J, Wu MC, et al
    High body mass index and the risk of hepatocellular carcinoma.
    Gut. 2017 Jun 7. pii: gutjnl-2017-314259. doi: 10.1136/gutjnl-2017-314259.

  226. BAJAJ JS, Liu EJ, Kheradman R, Fagan A, et al
    Fungal dysbiosis in cirrhosis.
    Gut. 2017 Jun 3. pii: gutjnl-2016-313170. doi: 10.1136/gutjnl-2016-313170.
    PubMed     Abstract available

  227. KULLAK-UBLICK GA, Andrade RJ, Merz M, End P, et al
    Drug-induced liver injury: recent advances in diagnosis and risk assessment.
    Gut. 2017;66:1154-1164.
    PubMed     Abstract available

  228. ADAMS LA, Anstee QM, Tilg H, Targher G, et al
    Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
    Gut. 2017;66:1138-1153.
    PubMed     Abstract available

  229. BROOKS AJ, Smith PJ, Cohen R, Collins P, et al
    UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care.
    Gut. 2017;66:988-1000.
    PubMed     Abstract available

    May 2017
  230. PANKOWICZ FP, Jarrett KE, Lagor WR, Bissig KD, et al
    CRISPR/Cas9: at the cutting edge of hepatology.
    Gut. 2017 May 9. pii: gutjnl-2016-313565. doi: 10.1136/gutjnl-2016-313565.
    PubMed     Abstract available

  231. THOMAS E
    Hepatitis B virus X protein: TRIMming antiviral defences in hepatocytes.
    Gut. 2017 May 5. pii: gutjnl-2017-314013. doi: 10.1136/gutjnl-2017-314013.

  232. BREITKOPF-HEINLEIN K, Meyer C, Konig C, Gaitantzi H, et al
    BMP-9 interferes with liver regeneration and promotes liver fibrosis.
    Gut. 2017;66:939-954.
    PubMed     Abstract available

    April 2017
  233. TRIANTAFYLLOU E, Pop OT, Possamai LA, Wilhelm A, et al
    MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure.
    Gut. 2017 Apr 27. pii: gutjnl-2016-313615. doi: 10.1136/gutjnl-2016-313615.
    PubMed     Abstract available

  234. ALLWEISS L, Volz T, Giersch K, Kah J, et al
    Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
    Gut. 2017 Apr 20. pii: gutjnl-2016-312162. doi: 10.1136/gutjnl-2016-312162.
    PubMed     Abstract available

  235. HANIN G, Yayon N, Tzur Y, Haviv R, et al
    miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression.
    Gut. 2017 Apr 5. pii: gutjnl-2016-312869. doi: 10.1136/gutjnl-2016-312869.
    PubMed     Abstract available

  236. LI M, He Y, Zhou Z, Ramirez T, et al
    MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-p47phox-oxidative stress pathway in neutrophils.
    Gut. 2017;66:705-715.
    PubMed     Abstract available

  237. HUR K, Toiyama Y, Okugawa Y, Ide S, et al
    Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer.
    Gut. 2017;66:654-665.
    PubMed     Abstract available

  238. WANG S, Ding WX
    A small RNA in neutrophils protects against acute-on-chronic alcoholic liver injury.
    Gut. 2017;66:565-566.

    March 2017
  239. CARLONI V, Lulli M, Madiai S, Mello T, et al
    CHK2 overexpression and mislocalisation within mitotic structures enhances chromosomal instability and hepatocellular carcinoma progression.
    Gut. 2017 Mar 30. pii: gutjnl-2016-313114. doi: 10.1136/gutjnl-2016-313114.
    PubMed     Abstract available

  240. HAGSTROM H, Tynelius P, Rasmussen F
    High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men.
    Gut. 2017 Mar 20. pii: gutjnl-2016-313622. doi: 10.1136/gutjnl-2016-313622.
    PubMed     Abstract available

  241. PARSEUS A, Sommer N, Sommer F, Caesar R, et al
    Microbiota-induced obesity requires farnesoid X receptor.
    Gut. 2017;66:429-437.
    PubMed     Abstract available

    February 2017
  242. SINN DH, Kang D, Chang Y, Ryu S, et al
    Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study.
    Gut. 2017;66:323-329.
    PubMed     Abstract available

  243. TARGHER G
    Non-alcoholic fatty liver disease as driving force in coronary heart disease?
    Gut. 2017;66:213-214.

    January 2017
  244. ROTMAN Y, Sanyal AJ
    Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
    Gut. 2017;66:180-190.
    PubMed     Abstract available

  245. LI X, Yao W, Yuan Y, Chen P, et al
    Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Gut. 2017;66:157-167.
    PubMed     Abstract available

  246. AUGUSTIN S, Pons M, Genesca J
    Ruling in and ruling out with elastography in compensated advanced chronic liver disease.
    Gut. 2017;66:197-198.

    September 2016
  247. SINGH A, Smith PJ, Cropley IM, Planche KL, et al
    Gallstone mimicry: a rare cause of abdominal pain.
    Gut. 2016 Sep 29. pii: gutjnl-2016-312706. doi: 10.1136/gutjnl-2016-312706.

    July 2016
  248. GRILLET F, Bayet E, Villeronce O, Zappia L, et al
    Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture.
    Gut. 2016 Jul 25. pii: gutjnl-2016-311447. doi: 10.1136/gutjnl-2016-311447.
    PubMed     Abstract available

    March 2016
  249. GRIESMANN H, Drexel C, Milosevic N, Sipos B, et al
    Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer.
    Gut. 2016 Mar 24. pii: gutjnl-2015-310049. doi: 10.1136/gutjnl-2015-310049.
    PubMed     Abstract available

    February 2016
  250. EHLKEN H, Wroblewski R, Corpechot C, Arrive L, et al
    Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis.
    Gut. 2016 Feb 26. pii: gutjnl-2016-311452. doi: 10.1136/gutjnl-2016-311452.

  251. COLOMBEL JF, Sands BE, Rutgeerts P, Sandborn W, et al
    The safety of vedolizumab for ulcerative colitis and Crohn's disease.
    Gut. 2016 Feb 18. pii: gutjnl-2015-311079. doi: 10.1136/gutjnl-2015-311079.
    PubMed     Abstract available

    September 2015
  252. KLEIN S, Rick J, Lehmann J, Schierwagen R, et al
    Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
    Gut. 2015 Sep 17. pii: gutjnl-2015-309600. doi: 10.1136/gutjnl-2015-309600.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.